Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. Abstract Text:

ABSTRACT: BACKGROUND: Although the PBS-IIc SELDI-TOF MS apparatus has been extensively used in the search for better biomarkers, issues have been raised concerning the semi-quantitative nature of the technique and its reproducibility. To overcome these limitations, a new SELDI-TOF MS instrument has been introduced: the PCS 4000 series. Changes in this apparatus compared to the older one are a.o. an increased dynamic range of the detector, an adjusted configuration of the detector sensitivity, a raster scan that ensures more complete desorption coverage and an improved detector attenuation mechanism. In the current study, we evaluated the performance of the old PBS-IIc and new PCS 4000 series generation SELDI-TOF MS apparatus. METHODS: To this end, two different sample sets were profiled after which the same ProteinChip arrays were analysed successively by both instruments. Generated spectra were analysed by the associated software packages. The performance of both instruments was evaluated by assessment of the number of peaks detected in the two sample sets, the biomarker potential and reproducibility of generated peak clusters, and the number of peaks detected following serum fractionation. RESULTS: We could not confirm the claimed improved performance of the new PCS 4000 instrument, as assessed by the number of peaks detected, the biomarker potential and the reproducibility. However, the PCS 4000 instrument did prove to be of superior performance in peak detection following profiling of serum fractions. CONCLUSION: As serum fractionation facilitates detection of low abundant proteins through reduction of the dynamic range of serum proteins, it is now increasingly applied in the search for new potential biomarkers. Hence, although the new PCS 4000 instrument did not differ from the old PBS-IIc apparatus in the analysis of crude serum, its superior performance after serum fractionation does hold promise for improved biomarker detection and identification.

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BMC medical genomics

VOLUME: 1

Page Numbers: 4

Journal Abbreviation:

ISSN: 1755-8794

DAY: 31

MONTH: 01

YEAR: 2008

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101319628

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.

AFFILIATION: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands. Marie-Christine.Gast@slz.nl.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BMC Med Genomics

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling Related Publications

• A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
• Amyloid Beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
• Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.
• Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
• Didanosine, a new antiretroviral drug. A review.
• Dideoxynucleoside therapy for HIV infection.
• Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
• Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.
• Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin(R) g
• Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.
• Home-based chemotherapy confronts pharmacists with stability and compatibility problems.
• Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.
• Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.
• Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH(4) with biomarker potential in human plasma and serum.
• New cytotoxic drugs and targets in oncology.
• Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
• Platinum antitumour agents: a review of (bio)analysis.
• Prescription error resulting in valproic acid intoxication.
• Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry.
• Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.
• Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.
• Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS).
• The risks of handling cytotoxic drugs. I. Methods of testing exposure.
• The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.